S&P Global Ratings has revised its outlook on McKesson Corp (NYSE:MCK). to positive from stable, while affirming its 'BBB+' ...

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

In a report released yesterday, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...

In a report released today, Allen Lutz from Bank of America Securities maintained a Buy rating on McKesson (MCK – Research Report). The ...

Investors should watch how McKesson navigates competitive and regulatory pressure. Notable competitors like Cardinal Health could challenge McKesson's market position. Upcoming quarters may see ...

McKesson MCK has started 2025 on a positive ... MCK’s industry peers, like Cardinal Health CAH and Cencora COR, have also registered strong growth year to date. MCK stock is currently trading ...

Its two close competitors are Cencora and McKesson. Together, the three operate as a pharmaceutical wholesale and distribution oligopoly, supplying over 90% of the US market. Narrow-moat Cardinal ...

Please stand by. Welcome to McKesson's third quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over ...

McKesson acquires 80% of PRISM Vision Holdings for $850M, expanding their presence in ophthalmology and retina management services.